COMMUNIQUÉS West-GlobeNewswire

LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
23/01/2025
LPX-TI641 is a novel, orally bioavailable, potent small-molecule immunomodulator that restores immune tolerance by targeting multiple pathways implicated in autoimmune diseases. Topline Phase 1 clinical data for LPX- [...]
DLH to Announce Fiscal 2025 First Quarter Financial Results
23/01/2025
ATLANTA, Jan. 23, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
23/01/2025
Data presented at Hawaiian Eye and Retina 2025 Meeting Results confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safety ONS-5010 [...]
PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider
23/01/2025
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS) at [...]
Persephone Biosciences Announces First Subject Enrolled in ARTEMIS Clinical Trial of New Infant Synbiotic
23/01/2025
- Up to 200 subjects will receive four curated strains never before given in combination as a synbiotic treatment, as part of a development plan to improve infant health outcomes - SAN DIEGO, Jan. 23, 2025 (GLOBE [...]
PathAI Partners with Discovery Life Sciences to Deploy First AI-Powered Biospecimen Solutions
23/01/2025
Collaboration Marks First At-Scale Deployment of AI Technologies into Leading Commercial Biobank BOSTON and HUNTSVILLE, Ala, Jan. 23, 2025 (GLOBE NEWSWIRE) -- PathAI, a leading provider of AI-powered technology for [...]
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
23/01/2025
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
23/01/2025
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety [...]
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
23/01/2025
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), [...]
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
23/01/2025
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information [...]
Safety Shot Reaches an Amicable Litigation Settlement Agreement, Strengthening Financial Position and Fostering Strategic Partnerships
23/01/2025
SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today announced that it has reached a settlement [...]
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
23/01/2025
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints Observed Data Supports QRX003 Mechanism of Action as a Competitive Broad [...]
Inteleos Foundation Announces Two New Global Health Leaders to 2025 Board Directors
23/01/2025
ROCKVILLE, Md., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The Inteleos Foundation, an international nonprofit organization driving access to medical imaging, has announced the addition of two esteemed members to the Board of [...]
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
23/01/2025
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without [...]
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
23/01/2025
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap [...]
AMN Healthcare to Hold Fourth Quarter and Full Year 2024 Earnings Conference Call on Thursday, February 20, 2025
23/01/2025
DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its fourth quarter and full year 2024 financial results and first quarter 2025 outlook on [...]
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
23/01/2025
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights e vorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized [...]
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
23/01/2025
Exploring the combination with azacitidine Study led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
23/01/2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company [...]

Pages